Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the appro

See more here: 
European Medical Advisory Committee Does Not Recommend Approval Of Avastin For Deadly Form Of Brain Cancer

Related posts:

1. FDA Advisory Committee Recommends Against Approving Tarceva For First-Line Maintenance Use In Advanced Non-Small Cell Lung CancerOSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) Oncologic...
2. European CHMP Formally Adopts Negative Opinion On Oncophage(R)Antigenics Inc. (NASDAQ: AGEN) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion...
3. MagForce Nanotechnologies AG Applies For European Regulatory Approval Of Its Nano-Cancer(R) TherapyMagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products....
4. Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance For Proposed INTERCEPT Blood System Phase III Trial DesignCerus Corporation (NASDAQ:CERS) announced that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III...
5. Amgen Receives CHMP Positive Opinion For Prolia(TM) (Denosumab) In The European UnionAmgen Inc. (Nasdaq: AMGN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization...
6. FDA Advisory Committee Supports Use Of Aztreonam For Inhalation Solution For Patients With Cystic FibrosisGilead Sciences, Inc. (Nasdaq: GILD) announced that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended that aztreonam for inhalation solution be approved for...
7. Ouroboros Medical Inc. Establishes European Approval And Awarded 2009 Spine Technology Summit AwardOuroboros Medical, Inc., an early stage medical device company focused on developing minimally invasive spine products for degenerated disc disease, has received approval to market Ouroboros's spinal fusion product in...
8. World’s First Delivery Of Intra-Arterial Avastin Directly Into Brain TumorNeurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. ...
9. Patient Receives World’s First Delivery Of Intra-arterial Avastin Directly Into A Malignant Brain TumorNeurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. ...
10. Independent Advisory Committee Recommends Continuation Of Phase III Oral Calcitonin Studies For Osteoporosis And OsteoarthritisUnigene Laboratories, Inc. (OTCBB: UGNE) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin...
11. Basilea’s Toctino(R) Recommended For Approval In 15 Additional European CountriesBasilea Pharmaceutica Ltd. (SWISS: BSLN) announces that Toctino® (alitretinoin) was recommended for regulatory approval under the Repeat-use Procedure in 13 additional European Union (EU) Member States as well as in...
12. Merck KGaA: CHMP Opinion For Erbitux In Advanced Non-Small Cell Lung CancerThe Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux® (cetuximab) in...
13. Nanostart-Owned MagForce Nanotechnologies AG: Application Submitted For EU Regulatory Approval Of Nano-Cancer(R) TherapyMagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy. The application is based...
14. Gore Receives European CE Mark Approval For Next Generation Conformable GORE TAG(R) Thoracic EndoprosthesisW.L. Gore & Associates (Gore) announced that it has received European CE Mark approval for the next generation GORE TAG® Thoracic Endoprosthesis. ...
15. The Medicines Company Receives European Approval For Angiox(R) (Bivalirudin) For Use In Heart Attack Patients Undergoing Emergency Heart ProceduresThe Medicines Company (NASDAQ: MDCO) announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation...